Merck KGaA Invests in Biopharmaceuticals Fill-Finish Site - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Merck KGaA Invests in Biopharmaceuticals Fill-Finish Site


Merck KGaA plans to invest €50 million (68 million USD) in its Italian production site in Bari to respond to the rising demand for biopharmaceuticals, the company announced in a press release. The expansion is part of the company's "Fit for 2018" transformation and growth program.

Within the biopharmaceuticals division, the Bari site is part of Merck's fill & finish operations, along with facilities in Darmstadt and Aubonne (Switzerland). The drugs produced within this global network, particularly those used to treat infertility, are experiencing long-term growing demand. The new production facility in Bari will be commissioned in 2017 for the sterile filling and packaging of liquid drugs into syringes, vials, and ampoules.

Source: Merck KGaA

 

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
8%
Protecting the supply chain
40%
Expedited reviews of drug submissions
8%
More stakeholder involvement
12%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here